• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

创伤性硬脑膜下血肿后重启抗凝和抗血小板治疗的时机:单中心经验。

Timing of Restarting Anticoagulation and Antiplatelet Therapies After Traumatic Subdural Hematoma-A Single Institution Experience.

机构信息

Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA.

University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota, USA.

出版信息

World Neurosurg. 2021 Jun;150:e203-e208. doi: 10.1016/j.wneu.2021.02.135. Epub 2021 Mar 5.

DOI:10.1016/j.wneu.2021.02.135
PMID:33684586
Abstract

BACKGROUND

There is a paucity of information regarding the optimal timing of restarting antiplatelet therapy (APT) and anticoagulation therapy (ACT) after traumatic subdural hematoma (tSDH). Therefore, we sought to report our experience at a single level 1 trauma center with regard to restarting APT and/or ACT after tSDH.

METHODS

A total of 456 consecutive records were reviewed for unplanned hematoma evacuation within 90 days of discharge and thrombotic/thromboembolic events before restarting APT and/or ACT.

RESULTS

There was no difference in unplanned hematoma evacuation rate in patients not receiving APT or ACT (control) compared with those necessitating APT and/or ACT (6.4% control, 6.9% APT alone, 5.8% ACT alone, 5.4% APT and ACT). There was an increase in post-tSDH thrombosis/thromboembolism in patients needing to restart ACT (1.9% APT alone, P = 0.53 vs. control; 5.8% ACT alone, P = 0.04 vs. control; 16% APT and ACT; P < 0.001 vs. control). Subgroup analysis revealed that patients with coronary artery disease necessitating APT and patients with atrial fibrillation necessitating ACT had higher thrombosis/thromboembolism rates compared with controls (1.0% control vs. 6.1% coronary artery disease, P = 0.02; 1.0% control vs. 10.1% atrial fibrillation, P < 0.001). The median restart time of ACT was approximately 1 month after trauma; APT was restarted 2-4 weeks after trauma depending on clinical indication.

CONCLUSIONS

Patients requiring reinitiation of APT and/or ACT after tSDH were at elevated risk of thrombotic/thromboembolic events but not unplanned hematoma evacuation. Therefore, patients should be followed closely until APT and/or ACT are restarted, and consideration for earlier reinitiation of blood thinners should be given on a case-by-case basis.

摘要

背景

关于创伤性硬脑膜下血肿(tSDH)后重新开始抗血小板治疗(APT)和抗凝治疗(ACT)的最佳时机,信息匮乏。因此,我们旨在报告我们在单一 1 级创伤中心的经验,涉及 tSDH 后重新开始 APT 和/或 ACT。

方法

回顾了 456 例连续记录,以了解出院后 90 天内计划外血肿清除和重新开始 APT 和/或 ACT 前血栓形成/栓塞事件的情况。

结果

未接受 APT 或 ACT(对照组)的患者与需要 APT 和/或 ACT 的患者(6.4%对照组、6.9%单独 APT、5.8%单独 ACT、5.4% APT 和 ACT)之间的计划外血肿清除率无差异。需要重新开始 ACT 的患者在 tSDH 后血栓形成/栓塞的发生率增加(1.9%单独 APT,P=0.53 与对照组;5.8%单独 ACT,P=0.04 与对照组;16% APT 和 ACT;P<0.001 与对照组)。亚组分析显示,需要 APT 的冠状动脉疾病患者和需要 ACT 的心房颤动患者的血栓形成/栓塞发生率高于对照组(1.0%对照组与 6.1%冠状动脉疾病,P=0.02;1.0%对照组与 10.1%心房颤动,P<0.001)。ACT 的中位数重新开始时间约为创伤后 1 个月;APT 根据临床指征在创伤后 2-4 周重新开始。

结论

tSDH 后需要重新开始 APT 和/或 ACT 的患者发生血栓形成/栓塞事件的风险较高,但计划外血肿清除的风险并不高。因此,应密切随访患者,直到重新开始 APT 和/或 ACT,并应根据具体情况考虑更早地重新开始使用血液稀释剂。

相似文献

1
Timing of Restarting Anticoagulation and Antiplatelet Therapies After Traumatic Subdural Hematoma-A Single Institution Experience.创伤性硬脑膜下血肿后重启抗凝和抗血小板治疗的时机:单中心经验。
World Neurosurg. 2021 Jun;150:e203-e208. doi: 10.1016/j.wneu.2021.02.135. Epub 2021 Mar 5.
2
Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review.合并抗凝和抗血小板治疗用于伴有房颤的高危患者:一项系统评价。
Health Technol Assess. 2013 Jul;17(30):1-188. doi: 10.3310/hta17300.
3
Propensity-Matched Comparison of Oral Anticoagulation Versus Antiplatelet Therapy After Left Atrial Appendage Closure With WATCHMAN.经 WATCHMAN 左心耳封堵术后口服抗凝与抗血小板治疗的倾向性匹配比较。
JACC Cardiovasc Interv. 2019 Jun 10;12(11):1055-1063. doi: 10.1016/j.jcin.2019.04.004.
4
Short-Term Oral Anticoagulation Versus Antiplatelet Therapy Following Transcatheter Left Atrial Appendage Closure.经导管左心耳封堵术后短期口服抗凝治疗与抗血小板治疗的比较
Circ Cardiovasc Interv. 2020 Aug;13(8):e009039. doi: 10.1161/CIRCINTERVENTIONS.120.009039. Epub 2020 Aug 10.
5
Anticoagulants versus Antiplatelet Treatment in the Medical Management of Carotid Floating Thrombus.抗凝血剂与抗血小板治疗在颈动脉漂浮血栓的医学管理中的应用。
J Stroke Cerebrovasc Dis. 2024 Jul;33(7):107760. doi: 10.1016/j.jstrokecerebrovasdis.2024.107760. Epub 2024 May 7.
6
Open-Label Randomized Trial Comparing Oral Anticoagulation With and Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent Implantation.经皮冠状动脉介入治疗 1 年后合并心房颤动和稳定型冠状动脉疾病患者双联抗血小板治疗与单抗血小板治疗的开放性随机临床试验比较
Circulation. 2019 Jan 29;139(5):604-616. doi: 10.1161/CIRCULATIONAHA.118.036768.
7
Role of antithrombotic therapy in the risk of hematoma recurrence and thromboembolism after chronic subdural hematoma evacuation: a population-based consecutive cohort study.抗血栓治疗在慢性硬膜下血肿清除术后血肿复发和血栓栓塞风险中的作用:一项基于人群的连续队列研究。
Acta Neurochir (Wien). 2017 Nov;159(11):2045-2052. doi: 10.1007/s00701-017-3330-x. Epub 2017 Sep 27.
8
Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events.在患有稳定型冠状动脉疾病和心房颤动的门诊患者中使用或不使用长期抗血小板治疗的维生素K拮抗剂:与缺血性和出血性事件的关联
Clin Cardiol. 2017 Oct;40(10):932-939. doi: 10.1002/clc.22750. Epub 2017 Jul 10.
9
Acute Traumatic Subdural Hematoma and Anticoagulation Risk.急性创伤性硬脑膜下血肿与抗凝风险
Can J Neurol Sci. 2023 Mar;50(2):188-193. doi: 10.1017/cjn.2021.518. Epub 2022 Jan 3.
10
Does antiplatelet therapy affect outcomes of patients receiving abdominal laparoscopic surgery? Lessons from more than 1,000 laparoscopic operations in a single tertiary referral hospital.抗血小板治疗是否会影响接受腹部腹腔镜手术患者的结局?来自一家三级转诊医院的 1000 多例腹腔镜手术的经验教训。
J Am Coll Surg. 2013 Dec;217(6):1044-53. doi: 10.1016/j.jamcollsurg.2013.08.005. Epub 2013 Sep 17.

引用本文的文献

1
Anticoagulation Therapy and Severe Traumatic Brain Injury: A Retrospective Cohort Study on Clinical Outcomes Using TriNetX.抗凝治疗与重度创伤性脑损伤:一项使用TriNetX的临床结局回顾性队列研究
J Clin Med. 2025 Jun 25;14(13):4510. doi: 10.3390/jcm14134510.
2
Traumatic Brain Injury in Patients under Anticoagulant Therapy: Review of Management in Emergency Department.接受抗凝治疗患者的创伤性脑损伤:急诊科管理综述
J Clin Med. 2024 Jun 24;13(13):3669. doi: 10.3390/jcm13133669.
3
Anticoagulation and Antiplatelet Agent Resumption Timing following Traumatic Brain Injury.
创伤性脑损伤后抗凝和抗血小板药物的恢复时机
Korean J Neurotrauma. 2023 Sep 12;19(3):298-306. doi: 10.13004/kjnt.2023.19.e42. eCollection 2023 Sep.
4
Anticoagulation Holiday: Resumption of Direct Oral Anticoagulants for Atrial Fibrillation in Patients with Index Traumatic Intracranial Hemorrhage.抗凝假期:创伤性颅内出血患者房颤患者直接口服抗凝剂的恢复使用
World Neurosurg X. 2022 Oct 12;17:100148. doi: 10.1016/j.wnsx.2022.100148. eCollection 2023 Jan.